Alnylam Pharmaceuticals (ALNY) Total Current Liabilities (2009 - 2026)

Alnylam Pharmaceuticals' Total Current Liabilities history runs 18 years deep, the most recent figure standing at $1.3 billion for Q1 2026.

• Quarterly Total Current Liabilities rose 25.46% year-over-year to $1.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 25.46% YoY) and the FY2025 annual result came in at $1.5 billion, up 23.61% from the prior year.
• Total Current Liabilities was $1.3 billion for Q1 2026 at Alnylam Pharmaceuticals, down from $1.5 billion in the prior quarter.
• Across five years, Total Current Liabilities topped out at $1.6 billion in Q3 2025 and bottomed at $606.0 million in Q1 2022.
• A 5-year average of $1.0 billion and a median of $967.8 million in 2023 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Current Liabilities rose 10.38% — and 2024, when it surged 39.85%.
• Alnylam Pharmaceuticals' Total Current Liabilities stood at $767.9 million in 2022, then gained by 26.03% to $967.8 million in 2023, then advanced by 22.58% to $1.2 billion in 2024, then gained by 23.61% to $1.5 billion in 2025, then dropped by 7.97% to $1.3 billion in 2026.
• Business Quant data shows ALNY's Total Current Liabilities at $1.3 billion in Q1 2026, $1.5 billion in Q4 2025, and $1.6 billion in Q3 2025.